title: Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management.
abstract: Despite increasing reports of life-threatening Fusarium infections, little is known about its pathogenesis and management. To evaluate the epidemiology, clinicopathologic features, and outcome of invasive fusariosis in patients with hematologic cancer, we conducted a retrospective study of invasive fusarial infections in patients with hematologic malignancy treated at a referral cancer center over a 10-year period (1986 to 1995), as well as a literature review. Forty patients with disseminated and three patients with invasive lung infection were included in the analysis. All patients were immunocompromised. The infection occurred in three patients postengraftment following bone marrow transplantation. All patients were diagnosed antemortem. Thirteen patients responded to therapy, but the infection relapsed in two of them. Response was associated with granulocyte transfusions, amphotericin B lipid formulations (four patients each), and an investigational triazole (two patients). Resolution of infection was only seen in patients who ultimately recovered from myelosuppression. Portal of entry was the skin (33%), the sinopulmonary tree (30%), and unknown (37%). Fusarium causes serious morbidity and mortality, and may mimic aspergillosis. The infection seems to respond to newer therapeutic approaches, but only in patients with ultimate recovery from myelosuppression, and it may relapse if neutropenia recurs.
authors.affiliation: The University of Texas M.D. Anderson Cancer Center, Houston, USA.
authors.forename: E I
authors.initials: EI
authors.lastname: Boutati
authors.forename: E J
authors.initials: EJ
authors.lastname: Anaissie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002173:Cancer Care Facilities; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology; D005670:Fusarium / Q000302:isolation & purification / Q000472:pathogenicity; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D017708:Leukocyte Transfusion; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology*; D009503:Neutropenia / Q000209:etiology / Q000628:therapy; D012008:Recurrence; D012189:Retrospective Studies; D012867:Skin / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents